Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.
2.

Interview with Steven A. Haney, PhD.

Haney SA, Glaser V.

Assay Drug Dev Technol. 2014 Jan-Feb;12(1):12-5. doi: 10.1089/adt.2014.1201.pr. No abstract available.

PMID:
24547741
3.

siRNA off-target effects can be reduced at concentrations that match their individual potency.

Caffrey DR, Zhao J, Song Z, Schaffer ME, Haney SA, Subramanian RR, Seymour AB, Hughes JD.

PLoS One. 2011;6(7):e21503. doi: 10.1371/journal.pone.0021503. Epub 2011 Jul 5.

4.

Single cell cytometry of protein function in RNAi treated cells and in native populations.

LaPan P, Zhang J, Pan J, Hill A, Haney SA.

BMC Cell Biol. 2008 Aug 1;9:43. doi: 10.1186/1471-2121-9-43.

5.

Expanding the repertoire of RNA interference screens for developing new anticancer drug targets.

Haney SA.

Expert Opin Ther Targets. 2007 Nov;11(11):1429-41. Review.

PMID:
18028008
6.

Increasing the robustness and validity of RNAi screens.

Haney SA.

Pharmacogenomics. 2007 Aug;8(8):1037-49. Review.

PMID:
17716236
7.

Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized.

Li Y, Pan J, Li JL, Lee JH, Tunkey C, Saraf K, Garbe JC, Whitley MZ, Jelinsky SA, Stampfer MR, Haney SA.

Mol Cancer. 2007 Jan 18;6:7.

8.

High-content screening moves to the front of the line.

Haney SA, LaPan P, Pan J, Zhang J.

Drug Discov Today. 2006 Oct;11(19-20):889-94. Epub 2006 Sep 7. Review.

PMID:
16997138
9.

Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design.

Tsao DH, Sutherland AG, Jennings LD, Li Y, Rush TS 3rd, Alvarez JC, Ding W, Dushin EG, Dushin RG, Haney SA, Kenny CH, Malakian AK, Nilakantan R, Mosyak L.

Bioorg Med Chem. 2006 Dec 1;14(23):7953-61. Epub 2006 Aug 17.

PMID:
16919463
10.
11.
12.

Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction.

Jennings LD, Foreman KW, Rush TS 3rd, Tsao DH, Mosyak L, Kincaid SL, Sukhdeo MN, Sutherland AG, Ding W, Kenny CH, Sabus CL, Liu H, Dushin EG, Moghazeh SL, Labthavikul P, Petersen PJ, Tuckman M, Haney SA, Ruzin AV.

Bioorg Med Chem. 2004 Oct 1;12(19):5115-31. Erratum in: Bioorg Med Chem. 2005 Oct 15;13(20):5884. Haney, Steven A [added].

PMID:
15351395
14.

Genomics in anti-infective drug discovery--getting to endgame.

Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ.

Curr Pharm Des. 2002;8(13):1099-118. Review.

PMID:
12052222
15.

Genetic selection in Saccharomyces of mutant mammalian adenylyl cyclases with elevated basal activities.

Haney SA, Xu J, Lee SY, Ma CL, Duzic E, Broach JR, Manfredi JP.

Mol Genet Genomics. 2001 Aug;265(6):1120-8.

PMID:
11523785
16.
17.

CAC3(MSI1) suppression of RAS2(G19V) is independent of chromatin assembly factor I and mediated by NPR1.

Johnston SD, Enomoto S, Schneper L, McClellan MC, Twu F, Montgomery ND, Haney SA, Broach JR, Berman J.

Mol Cell Biol. 2001 Mar;21(5):1784-94.

19.

Lrp, a leucine-responsive protein, regulates branched-chain amino acid transport genes in Escherichia coli.

Haney SA, Platko JV, Oxender DL, Calvo JM.

J Bacteriol. 1992 Jan;174(1):108-15.

20.

Amino acid transport in bacteria.

Haney SA, Oxender DL.

Int Rev Cytol. 1992;137:37-95. Review. No abstract available.

PMID:
1428673
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk